Key Commercial Manufacturing Contract by LOTTE Biologics

AI Summary

LOTTE Biologics, with its co-CEO James Park as well as Yoo-yeol Shin,ย announced a key commercial manufacturing contract with a global pharmaceutical company on November 17, 2026, representing a major step in the commercialization of its Songdo Bio Campus.

The pact is the first significant commercial manufacturing deal for Songdo Plant 1, which was signed even before its operations began. LOTTE Biologics will offer integrated drug substance along with drug product manufacturing services to support major products in the customerโ€™s standard product line under the agreement, with commercial production planned to start in 2027.

Growth strategy validated by early commercial success

The signing of this key commercial manufacturing contract by LOTTE during the facility development phase demonstrates consumer trust in theย technical expertise, implementation performance, and long-term supply dependability of LOTTE Biologics.

LOTTE Biologics is speeding up its journey to commercialization and building a solid foundation for sustainable development, syncingย capacity expansion with customer objectives from the very beginning.

Advanced Infrastructure Designed for Global Biologics Production

Songdo Plant 1 has been developed to satisfy the changing demands of global biopharmaceutical manufacturing and is equipped with cutting-edge production facilities, sophisticated automation, and massive cold-chain warehousing to enable effective, dependable, and quality-focused operations.

The Songdo Bio Campus is being constructed with an overall capacity of 360,000 liters distributed among three plants, with Plant 1 offering a capacity of 120,000 liters in 8 stainless-steel bioreactors of 15,000 liters each.

The facility will be an addition to theย Syracuse Bio Campus from LOTTE Biologicsย in New York, which has over twenty years of manufacturing experience, a proven record of facilitating more thanย 62 regulatory authorizations, and a recent FDA evaluation with no observations.

Together they create an integrated global manufacturing network built to provide operational adaptability, uniform quality requirements, and enhanced supply chain resilience.

Creating a Differentiated Global CMO

LOTTE Biologics is emerging as a viable ally for global biologics manufacturing as pharmaceutical firms look for reputable manufacturing collaborators with established execution standards and geographically diverse supply networks.

The latest agreement is a concrete step in the direction of that goal, converting strategic investments into commercial obligations and bolstering the long-term growth path of the company.

According to Co-CEO of LOTTE Biologics, James Park, “This agreement is a strong endorsement of our strategy and the confidence our customers place in LOTTE Biologics. We are not simply building manufacturing capacity. We are building a globally integrated platform designed to deliver quality, reliability, and speed. By combining Syracuseโ€™s proven expertise with Songdoโ€™s advanced infrastructure, we are well positioned to support our partnersโ€™ success and bring life-changing medicines to patients worldwide.โ€

Popular:

Resilience And Growth In The U.S. Manufacturing Today

Strengthening U.S. Manufacturing: Strategies and Trends for Resilience As a...

Employing Digital Twins In Predictive Maintenance

When it comes to manufacturing, predictive maintenance goes on...

Navigating Geopolitics In The Global Trade Dynamics

Global trade continues to be a cornerstone of the...

Transforming The US Battery Manufacturing Industry

A $3 Billion Boost to Transform the US Battery...

Pharmaceutical Manufacturing & Advent of Pharma 4.0

Pharma 4.0 โ€“ What is it all about? It is...

BMW Opens Its First U.S. High-Voltage Battery Assembly Plant

The BMW Group has started operations at its first...

Semar to Open its First US Manufacturing Plant in Senatobia

In recent news, Italian transformer and power module manufacturer...

Oman, China Sign Largest Package of Investment Agreements

The Oman Investment Authority -ย OIA, which isย the sovereign wealth...

Anthropic Introduces Claude for Manufacturing with 17 Skills

On November 12, 2026, Anthropic has gone ahead and...

USD 1bn MDI Manufacturing Facility by BASF in Louisiana

BASF, which isย based in Germany, opened on November 11,...

Samsung Medison Builds New Manufacturing Facility

In a recent move, Samsung Medison builds new manufacturingย facility...

US$3.5bn Manufacturing Facility in Pennsylvania by Lilly

Eli Lilly and Company, the big pharma firm, on...

Expansion of Manufacturing Capacity of BWX Technologies

The manufacturing capacity of BWX Technologiesย to produce large-scale nuclear...

Related Articles

Popular Categories

Never miss a Manufacturing headline

The Manufacturing industry moves fast โ€“ stay on top of it with our must-read briefings.

  • The top Manufacturing stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving Manufacturing trade
Translate ยป